安杰思收盘下跌1.42%，滚动市盈率19.25倍，总市值57.15亿元

Core Viewpoint - Anjias's stock closed at 70.57 yuan, down 1.42%, with a rolling PE ratio of 19.25 times, and a total market value of 5.715 billion yuan. The company ranks 41st in the medical device industry, which has an average PE of 52.71 times and a median of 37.14 times [1][2]. Company Overview - Anjias specializes in the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments, primarily focusing on GI, EMR/ESD, and ERCP diagnostic series and equipment [1]. - As of June 30, 2025, Anjias had 5,163 shareholders, an increase of 190 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]. Financial Performance - In the first quarter of 2025, Anjias reported a revenue of 129 million yuan, a year-on-year increase of 15.27%, and a net profit of 56.248 million yuan, up 6.57%, with a gross profit margin of 70.68% [1]. Industry Comparison - The average PE ratio for the medical device industry is 52.71 times, while the median is 37.14 times. Anjias's PE ratio of 19.25 times is significantly lower than both the industry average and median [2].